Skip to main content
    S

    Seres Therapeutics Inc (MCRB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.41
    +0.01 (+0.71%)

    Market Cap: $14.27M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Seres Therapeutics Inc (MCRB) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Seres Therapeutics (MCRB) trades at 6.6x sales and 0.7x book value. Its P/S of 6.6x is below its 10-year median of 13.0x. Its forward P/E is 10.8x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E10.8x
    Price to sales6.6x
    Price to book0.7x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S6.6xN/A13.0x
    Medians of month-end values through Oct 2026: 96 months (10-year).

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/S, its P/S ranged from 5.2x in 2019 to 670.5x in 2022.

    Year endPriceP/SP/B
    2025$14.88N/A3.0x
    2024$16.62N/A5.3x
    2023$28.00119.1xN/A
    2022$112.00670.5x65.0x
    2021$166.605.3x5.8x
    2020$490.0082.4x12.8x
    2019$69.005.2xN/A
    2018$90.406.5xN/A
    2017$202.8012.8x6.8x
    2016$198.0018.2x3.0x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About MCRB

    What is MCRB's forward P/E ratio?

    Seres Therapeutics has a forward P/E ratio of 10.8x.

    What is MCRB's price to sales ratio?

    Seres Therapeutics has a price to sales ratio of 6.6x.